STRO
Sutro Biopharma, Inc. NASDAQ Listed Sep 27, 2018$39.83
Mkt Cap $338.5M
52w Low $6.70
98.7% of range
52w High $40.25
50d MA $27.11
200d MA $14.67
P/E (TTM)
-1.6x
EV/EBITDA
-0.6x
P/B
—
Debt/Equity
-0.1x
ROE
144.3%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
1.31
50d MA
$27.11
200d MA
$14.67
Avg Volume
193.6K
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
111 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -8.16 | -5.29 | +35.2% | 21.33 | +8.8% | +10.5% | +10.2% | +16.8% | +14.5% | +13.0% | — |
| Nov 6, 2025 | AMC | -4.20 | -6.70 | -59.5% | 9.42 | -4.5% | -13.4% | -14.4% | -13.7% | -13.9% | -1.4% | — |
| Aug 7, 2025 | AMC | -0.39 | -0.14 | +64.1% | 8.00 | +0.5% | +0.2% | -3.4% | -2.0% | -3.5% | -2.5% | — |
| May 8, 2025 | AMC | -0.63 | -0.91 | -44.4% | 9.58 | +4.4% | -9.0% | -9.2% | -14.9% | -23.5% | -8.2% | — |
| Mar 13, 2025 | AMC | -0.86 | -0.89 | -3.5% | 12.50 | -20.1% | -35.2% | -25.4% | -28.3% | -34.3% | -36.3% | — |
| Nov 13, 2024 | AMC | -0.74 | -0.59 | +20.3% | 39.60 | -1.8% | -12.9% | -27.0% | -30.6% | -31.8% | -32.6% | — |
| Aug 13, 2024 | AMC | -0.76 | -0.59 | +22.4% | 32.20 | +10.2% | +11.5% | +25.5% | +30.7% | +42.9% | +48.1% | — |
| May 13, 2024 | AMC | -0.92 | -0.95 | -3.3% | 42.30 | -0.2% | +2.6% | -7.1% | -1.9% | -5.2% | +10.6% | — |
| Mar 25, 2024 | AMC | -0.82 | 0.42 | +151.2% | 32.70 | +17.4% | +27.8% | +50.8% | +72.8% | +63.0% | +55.7% | — |
| Nov 13, 2023 | AMC | -0.76 | -0.81 | -6.6% | 20.70 | -0.5% | +14.5% | +18.8% | +13.5% | +30.0% | +33.8% | — |
| Aug 10, 2023 | AMC | -0.73 | -0.64 | +12.3% | 43.40 | -2.8% | -1.8% | -1.2% | -1.6% | -7.6% | -3.0% | — |
| May 15, 2023 | AMC | -0.83 | -0.76 | +8.4% | 58.80 | -3.9% | -2.6% | -2.2% | -10.0% | -8.0% | -9.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Mizuho | Initiates | Outperform | $50 | $35.39 | $36.54 | +3.2% | +3.5% | +0.6% | +8.5% | +5.5% | +6.5% |
| Apr 23 | Citizens | Maintains | Market Outperform → Market Outperform | — | $35.53 | $35.93 | +1.1% | -2.0% | -6.2% | -5.5% | -2.4% | -0.4% |
| Apr 17 | Citizens | Maintains | Market Outperform → Market Outperform | — | $29.35 | $30.57 | +4.2% | +7.5% | +17.8% | +17.0% | +21.1% | +18.7% |
| Mar 25 | Deutsche Bank | Maintains | Buy → Buy | — | $23.57 | $24.38 | +3.4% | -0.3% | +5.7% | +3.6% | +2.2% | +5.7% |
| Mar 24 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $21.33 | $23.21 | +8.8% | +10.5% | +10.2% | +16.8% | +14.5% | +13.0% |
| Mar 24 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $21.33 | $23.21 | +8.8% | +10.5% | +10.2% | +16.8% | +14.5% | +13.0% |
| Jan 20 | Citizens | Upgrade | Market Perform → Market Outperform | — | $13.82 | $14.19 | +2.7% | +8.0% | +14.3% | +18.1% | +8.9% | +13.2% |
| Dec 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.98 | $9.83 | -1.5% | +3.9% | +4.0% | +7.7% | +15.1% | +11.2% |
| Aug 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $7.73 | $7.65 | -1.0% | +1.4% | -0.1% | +0.9% | +13.6% | +18.4% |
| Jun 16 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.99 | $8.70 | +8.9% | +10.3% | -1.1% | -0.6% | +0.3% | +0.0% |
| May 19 | BofA Securities | Maintains | Underperform → Underperform | — | $9.12 | $9.09 | -0.3% | -3.7% | -1.3% | -8.1% | -1.0% | +0.9% |
| Apr 29 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.97 | $8.70 | -3.0% | -2.5% | +17.1% | +19.3% | +22.6% | +17.1% |
| Mar 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $8.10 | $8.17 | +0.9% | +15.1% | +10.6% | +1.4% | -1.7% | -5.3% |
| Mar 14 | BofA Securities | Downgrade | Buy → Underperform | — | $12.50 | $9.99 | -20.1% | -35.2% | -25.4% | -28.3% | -34.3% | -36.3% |
| Mar 14 | Wedbush | Downgrade | Outperform → Neutral | — | $12.50 | $9.99 | -20.1% | -35.2% | -25.4% | -28.3% | -34.3% | -36.3% |
| Mar 14 | Citizens Capital Markets | Downgrade | Market Outperform → Market Perform | — | $12.50 | $9.99 | -20.1% | -35.2% | -25.4% | -28.3% | -34.3% | -36.3% |
| Dec 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $23.50 | $23.80 | +1.3% | +4.3% | -6.4% | -9.8% | -11.9% | -11.1% |
| Dec 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.50 | $23.80 | +1.3% | +4.3% | -6.4% | -9.8% | -11.9% | -11.1% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.90 | $29.10 | +0.7% | -4.8% | -6.6% | -7.6% | -12.5% | -13.1% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.10 | $33.50 | +1.2% | +14.5% | +15.7% | +15.7% | +13.9% | +12.1% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.10 | $33.50 | +1.2% | +14.5% | +15.7% | +15.7% | +13.9% | +12.1% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.00 | $44.60 | -0.9% | -17.8% | -10.9% | -12.2% | -12.9% | -16.2% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $45.00 | $44.60 | -0.9% | -17.8% | -10.9% | -12.2% | -12.9% | -16.2% |
| Aug 16 | Truist | Maintains | Buy → Buy | — | $40.40 | $40.40 | +0.0% | +4.2% | +13.9% | +18.1% | +12.9% | +12.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.20 | $35.50 | +10.2% | +11.5% | +25.5% | +30.7% | +42.9% | +48.1% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $43.40 | $43.40 | +0.0% | -9.4% | -4.4% | -7.6% | +7.8% | +4.6% |
| May 14 | Wedbush | Maintains | Outperform → Outperform | — | $42.30 | $42.20 | -0.2% | +2.6% | -7.1% | -1.9% | -5.2% | +10.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.30 | $42.20 | -0.2% | +2.6% | -7.1% | -1.9% | -5.2% | +10.6% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -4.1% | -6.9% | -13.8% |
| Apr 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -4.1% | -6.9% | -13.8% |
| Apr 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -4.1% | -6.9% | -13.8% |
| Apr 3 | Truist | Maintains | Buy → Buy | — | $50.90 | $51.90 | +2.0% | +0.0% | -3.3% | -4.1% | -6.9% | -13.8% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $49.30 | $49.70 | +0.8% | +14.6% | +8.1% | +3.2% | +3.2% | -0.2% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $41.80 | $42.60 | +1.9% | +17.9% | +35.2% | +27.5% | +21.8% | +21.8% |
| Mar 26 | Wedbush | Maintains | Outperform → Outperform | — | $32.70 | $38.40 | +17.4% | +27.8% | +50.8% | +72.8% | +63.0% | +55.7% |
| Mar 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $32.70 | $38.40 | +17.4% | +27.8% | +50.8% | +72.8% | +63.0% | +55.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.70 | $38.40 | +17.4% | +27.8% | +50.8% | +72.8% | +63.0% | +55.7% |
| Nov 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.70 | $23.40 | -1.3% | +3.8% | -0.8% | +13.5% | +16.9% | +13.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.70 | $20.60 | -0.5% | +14.5% | +18.8% | +13.5% | +30.0% | +33.8% |
| Oct 23 | Wedbush | Maintains | Outperform → Outperform | — | $31.90 | $31.90 | +0.0% | -7.5% | -12.9% | -11.6% | -14.7% | -19.7% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $44.00 | $44.00 | +0.0% | +2.7% | +3.2% | +2.7% | +4.5% | +3.2% |
| Aug 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $42.60 | $42.10 | -1.2% | +0.7% | +0.2% | -5.9% | -1.2% | +4.9% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $43.40 | $42.20 | -2.8% | -1.8% | -1.2% | -1.6% | -7.6% | -3.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.40 | $42.20 | -2.8% | -1.8% | -1.2% | -1.6% | -7.6% | -3.0% |
| Jun 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $52.50 | $52.60 | +0.2% | -3.0% | -5.0% | -11.4% | -11.4% | -10.9% |
| May 17 | JMP Securities | Maintains | Market Outperform → Outperform | — | $57.30 | $57.10 | -0.3% | +0.3% | -7.7% | -5.6% | -7.3% | -7.7% |
| May 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $57.30 | $57.10 | -0.3% | +0.3% | -7.7% | -5.6% | -7.3% | -7.7% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.80 | $56.50 | -3.9% | -2.6% | -2.2% | -10.0% | -8.0% | -9.7% |
| Apr 3 | JMP Securities | Maintains | Outperform → Outperform | — | $46.20 | $47.00 | +1.7% | +2.2% | -6.7% | -6.3% | -0.6% | -6.5% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $44.80 | $44.40 | -0.9% | +3.1% | +5.4% | -3.8% | -3.3% | +2.5% |
No insider trades available.
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
The termination of a material agreement signals potential operational disruption or loss of revenue/partnership benefits, requiring investors to assess impact on earnings guidance and competitive positioning.
Mar 23
8-K
Sutro Biopharma, Inc. -- 8-K Filing
Sutro Biopharma secured funding through an offering to support R&D, clinical development, manufacturing, and potential acquisitions for its biopharmaceutical pipeline.
Feb 10
Data updated apr 27, 2026 3:20am
· Source: massive.com